|
Conditioning, the Placebo Effect, and Psoriasis Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Conditioning, the Placebo Effect, and Psoriasis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Conditioning, the Placebo Effect, and Psoriasis Clinical research trials and Conditioning, the Placebo Effect, and Psoriasis medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Conditioning, the Placebo Effect, and Psoriasis. Conditioning, the Placebo Effect, and Psoriasis Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Conditioning, the Placebo Effect, and Psoriasis clinical trial. Participants frequently get the best healthcare available for their Conditioning, the Placebo Effect, and Psoriasis condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Conditioning, the Placebo Effect, and Psoriasis  Conditioning, the Placebo Effect, and Psoriasis
Conditioning, the Placebo Effect, and Psoriasis
For Condition: Psoriasis
Status: Recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: This study uses the psychological principle known as classical conditioning to try to improve the standard treatment of psoriasis. Classical conditioning is a process of behavioral modification in which a person learns to connect a certain response-in this case, improvement of psoriasis-with a new action, or stimulus-in this case, application of an inactive cream. The goal of this study is to show that people with psoriasis who are maintained on corticosteroid cream part of the time and an inactive (placebo) cream at other times will need a lower total amount of active medication over time than will people who are treated only with the active drug.
Details: The lack of scientific attention devoted to the placebo effect as a phenomenon in its own right probably reflects the paucity of theoretical positions within which to organize the existing data and design new research. This research addresses the clinical significance of behavior-immune system interactions. This study will capitalize on conditioned immunosuppressive responses to reduce the cumulative amount of corticosteroid medication used in the treatment of psoriasis. We will continue to treat patients with steroid, but will shift experimental patients from their current schedule of continuous reinforcement (active drug whenever medication is applied) to a partial schedule of reinforcement (active drug a percentage of the time and placebo alone at other times). To equate amount of medication, we will treat another group of patients with a reduced dose of steroid in a standard treatment regimen (continuous schedule of reinforcement). We hypothesize that, holding cumulative dose constant, a partial schedule of reinforcement will enable patients to be maintained on lower cumulative amounts of corticosteroid than patients treated under a continuous schedule of active drug. This is the first attempt to adopt conditioning principles and use schedules of reinforcement to design regimens of drug therapy. If proven effective, this new approach to pharmacotherapy and placebo effects is likely to stimulate new interdisciplinary research in neuropharmacology and behavioral pharmacology for the treatment of autoimmune disorders and a variety of other chronic diseases.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Psoriasis patients with mild to moderate lesions who are able to attend weekly clinic visits at either the University of Rochester School of Medicine and Dentistry in Rochester, NY, or Stanford University in Palo Alto, CA. - Patients must be in good health (as determined by prescreening examination). - Patients must not be using systemic treatment (for example, oral medications) or intralesional, UV, or topical therapies except bland emollients for at least 2 weeks before the start date of the study. - Patients must have chronic, stable plaque psoriasis with a score of greater than or equal to 7 on a routine 9-point Severity Index. Exclusion Criteria: - Use of immunosuppressive medication within the past 2 months. - Pregnant or sexually active women who do not use contraceptives. - Patients who cannot be monitored regularly. - History of allergy to corticosteroid or other study ointment components. - Patients who have more than 10 percent of body surface area covered by psoriatic lesions.
Total Enrollment: 60
Location and Contact Information:
Overall Study Official:
RobertAder, Principal Investigator, University of Rochester School of Medicine and Dentistry
Stanford University *Recruiting*
Palo Alto, California, 94305
United States
Recruiting Michael Davis
Adult Dermatology Clinic, Strong Memorial Hospital *Recruiting*
Rochester, New York, 14642
United States
Recruiting
Additional Information:
Study ID Numbers: NIAMS-051; R01 AR46825
Study Start Date: August 2000
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005922
Other Psoriasis Studies:
1. Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
2. A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
3. To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris
4. Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
5. Micellar Paclitaxel to Treat Severe Psoriasis
Related Studies:
Other Psoriasis Clinical Trials
Other California Clinical Trials
Other Palo Alto Clinical Trials
Conditioning, the Placebo Effect, and Psoriasis
|
|
|
|
|
|
|
|
